| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Palma Rocchi | |
| Wai-Lung Ng | |||
| Clément Paris | |||
| Khadija Shahed Khan | |||
| Fran Robson | |||
| Peter Barfuss | |||
| Sinem Demirbag | |||
| Thi Khanh Le | |||
| P2860 | cites work | The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase | Q21089768 |
| Antisense morpholino-oligomers directed against the 5' end of the genome inhibit coronavirus proliferation and growth | Q24563538 | ||
| Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses | Q24617467 | ||
| Changing the face of hepatitis C management - the design and development of sofosbuvir | Q27011203 | ||
| The human coronavirus 229E superfamily 1 helicase has RNA and DNA duplex-unwinding activities with 5'-to-3' polarity | Q27472951 | ||
| Ribonucleoside Analogue That Blocks Replication of Bovine Viral Diarrhea and Hepatitis C Viruses in Culture | Q27473305 | ||
| A second, non-canonical RNA-dependent RNA polymerase in SARS Coronavirus | Q27477549 | ||
| The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex | Q27477706 | ||
| Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase | Q27487986 | ||
| Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir) | Q27685318 | ||
| Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase | Q27697984 | ||
| Morpholino oligomers targeting the PB1 and NP genes enhance the survival of mice infected with highly pathogenic influenza A H7N7 virus | Q28272780 | ||
| Genome-wide analysis of protein-protein interactions and involvement of viral proteins in SARS-CoV replication | Q28473684 | ||
| In vitro reconstitution of SARS-coronavirus mRNA cap methylation | Q28473757 | ||
| Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics | Q28535361 | ||
| Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage | Q29615331 | ||
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges | Q86910883 | ||
| The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 | Q87000965 | ||
| Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses | Q87461510 | ||
| Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection | Q87461568 | ||
| Origin and evolution of pathogenic coronaviruses | Q87747946 | ||
| Therapeutic options for the 2019 novel coronavirus (2019-nCoV) | Q88045822 | ||
| Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice | Q88138949 | ||
| Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV | Q88486711 | ||
| Favipiravir, an anti-influenza drug against life-threatening RNA virus infections | Q89877245 | ||
| The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold | Q90356090 | ||
| Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study | Q90720676 | ||
| Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features | Q91021600 | ||
| An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice | Q91610063 | ||
| Structure of the RNA-dependent RNA polymerase from COVID-19 virus | Q91816382 | ||
| Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites | Q91863840 | ||
| Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency | Q91872888 | ||
| Zoonotic origins of human coronavirus 2019 (HCoV-19 / SARS-CoV-2): why is this work important? | Q92108887 | ||
| The Curious Case of the Nidovirus Exoribonuclease: Its Role in RNA Synthesis and Replication Fidelity | Q92800161 | ||
| The Architecture of SARS-CoV-2 Transcriptome | Q93208123 | ||
| Properties of Coronavirus and SARS-CoV-2 | Q93335273 | ||
| Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza | Q94469287 | ||
| Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir | Q94482766 | ||
| Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial | Q94657383 | ||
| Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial | Q94771078 | ||
| Structure of replicating SARS-CoV-2 polymerase | Q95301171 | ||
| Structural basis for RNA replication by the SARS-CoV-2 polymerase | Q95601567 | ||
| A unifying structural and functional model of the coronavirus replication organelle: Tracking down RNA synthesis | Q96222980 | ||
| Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic | Q96229880 | ||
| Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2 | Q97587089 | ||
| Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19 | Q97638936 | ||
| The enzymatic activity of the nsp14 exoribonuclease is critical for replication of MERS-CoV and SARS-CoV-2 | Q99557062 | ||
| Molecular epidemiology, evolution and phylogeny of SARS coronavirus | Q84315392 | ||
| Nucleoside analogues for the treatment of coronavirus infections | Q84315443 | ||
| Small-Molecule Antiviral β-d--Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance | Q84315917 | ||
| Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro | Q84360011 | ||
| Structural basis for the 3'-5' exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism | Q29616775 | ||
| SARS-CoV ORF1b-encoded nonstructural proteins 12-16: replicative enzymes as antiviral targets. | Q30355948 | ||
| T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro | Q30426020 | ||
| Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing | Q33576672 | ||
| Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase | Q33798503 | ||
| Morpholino antisense oligomers: the case for an RNase H-independent structural type | Q33901587 | ||
| Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design | Q34053804 | ||
| SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage | Q34102763 | ||
| Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes | Q34170781 | ||
| One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities | Q34218422 | ||
| Mechanism of nucleic acid unwinding by SARS-CoV helicase. | Q34277309 | ||
| Coronavirus subgenomic minus-strand RNAs and the potential for mRNA replicons | Q34292813 | ||
| Favipiravir (T-705), a novel viral RNA polymerase inhibitor | Q34374652 | ||
| Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease | Q34468689 | ||
| Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys | Q34516555 | ||
| Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis | Q34596952 | ||
| Telbivudine versus entecavir for nucleos(t)ide-naive HBeAg-positive chronic hepatitis B: a meta-analysis | Q34657410 | ||
| Antiviral agents acting as DNA or RNA chain terminators | Q34892252 | ||
| Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity | Q35079166 | ||
| Comparative analysis of RNA genomes of mouse hepatitis viruses | Q35237854 | ||
| RNA-RNA and RNA-protein interactions in coronavirus replication and transcription | Q35592218 | ||
| Coronavirus nonstructural protein 1: Common and distinct functions in the regulation of host and viral gene expression | Q35648811 | ||
| Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex | Q35910211 | ||
| Programmed -1 ribosomal frameshifting in the SARS coronavirus | Q35928490 | ||
| RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex | Q36066229 | ||
| Characterization of the Role of Hexamer AGUAAA and Poly(A) Tail in Coronavirus Polyadenylation | Q36168099 | ||
| High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. | Q36315521 | ||
| Nidovirales: evolving the largest RNA virus genome | Q36407103 | ||
| Nucleoside analogue delivery systems in cancer therapy | Q36945847 | ||
| Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in Modulation of the Innate Immune Response. | Q37069821 | ||
| The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world. | Q37094749 | ||
| Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles | Q37105681 | ||
| Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides | Q37396435 | ||
| The severe acute respiratory syndrome coronavirus Nsp15 protein is an endoribonuclease that prefers manganese as a cofactor | Q37596919 | ||
| Conventional and unconventional mechanisms for capping viral mRNA. | Q37964471 | ||
| Implications of altered replication fidelity on the evolution and pathogenesis of coronaviruses. | Q38031688 | ||
| Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. | Q38110693 | ||
| Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus | Q38275792 | ||
| Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers | Q38323658 | ||
| Antiviral Strategies Based on Lethal Mutagenesis and Error Threshold. | Q38570742 | ||
| Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. | Q38665457 | ||
| Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses | Q38719353 | ||
| Molecular mechanisms of coronavirus RNA capping and methylation | Q38723707 | ||
| Continuous and Discontinuous RNA Synthesis in Coronaviruses | Q38766707 | ||
| The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing. | Q38973838 | ||
| FDA-Approved Oligonucleotide Therapies in 2017. | Q39214058 | ||
| Coronavirus nsp6 proteins generate autophagosomes from the endoplasmic reticulum via an omegasome intermediate | Q39498858 | ||
| In vitro and in vivo activities of anti-influenza virus compound T-705. | Q39651429 | ||
| Mutagenesis of S-Adenosyl-l-Methionine-Binding Residues in Coronavirus nsp14 N7-Methyltransferase Demonstrates Differing Requirements for Genome Translation and Resistance to Innate Immunity. | Q39716333 | ||
| The RNA polymerase activity of SARS-coronavirus nsp12 is primer dependent | Q39934277 | ||
| In vitro and in vivo protection against the highly pathogenic H5N1 influenza virus by an antisense phosphorothioate oligonucleotide | Q39994934 | ||
| Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase | Q40044875 | ||
| The ProTide Prodrug Technology: From the Concept to the Clinic | Q40089234 | ||
| Inhibition of human coronavirus NL63 infection at early stages of the replication cycle | Q40275624 | ||
| The cellular and molecular pathogenesis of coronaviruses. | Q40852553 | ||
| Coronaviruses use discontinuous extension for synthesis of subgenome-length negative strands | Q41130601 | ||
| Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase | Q42110040 | ||
| Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity | Q42406865 | ||
| Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. | Q42556146 | ||
| β-D-N(4)-hydroxycytidine is a potent anti-alphavirus compound that induces high level of mutations in viral genome. | Q44170252 | ||
| Biochemical characterization of exoribonuclease encoded by SARS coronavirus | Q44542066 | ||
| Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine | Q44837571 | ||
| Cross-protective effect of antisense oligonucleotide developed against the common 3' NCR of influenza A virus genome | Q45350946 | ||
| Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. | Q47560362 | ||
| Designing Effective Antisense Oligonucleotides for Exon Skipping | Q47606988 | ||
| History and recent advances in coronavirus discovery | Q47663346 | ||
| Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer. | Q51020018 | ||
| The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. | Q52323442 | ||
| Nucleosides for the treatment of respiratory RNA virus infections. | Q52644426 | ||
| Addressing the selectivity and toxicity of antiviral nucleosides. | Q52657691 | ||
| Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds. | Q53687216 | ||
| Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. | Q53704198 | ||
| The Genome Organization of the Nidovirales: Similarities and Differences between Arteri-, Toro-, and Coronaviruses | Q56030398 | ||
| A planarian nidovirus expands the limits of RNA genome size | Q58085178 | ||
| Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis | Q64280977 | ||
| Coronaviruses, a new group of animal RNA viruses | Q68611598 | ||
| P921 | main subject | SARS-CoV-2 | Q82069695 |
| P577 | publication date | 2020-08-04 | |
| 2020-09-03 | |||
| P1433 | published in | Molecular Cell | Q3319468 |
| P1476 | title | Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting |
| Q108396003 | A high-resolution temporal atlas of the SARS-CoV-2 translatome and transcriptome |
| Q111442216 | An all-out assault on SARS-CoV-2 replication |
| Q108396862 | Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity |
| Q110257042 | Coronavirus genomic nsp14-ExoN, structure, role, mechanism, and potential application as a drug target |
| Q109649916 | Crystal structure of SARS-CoV-2 nsp10 bound to nsp14-ExoN domain reveals an exoribonuclease with both structural and functional integrity |
| Q108084260 | Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis |
| Q107343704 | Reconstitution and functional characterization of SARS-CoV-2 proofreading complex |
| Q107713920 | Remdesivir Is Effective in Combating COVID-19 because It Is a Better Substrate than ATP for the Viral RNA-Dependent RNA Polymerase |
| Q107011696 | Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir |
| Q107713706 | Structural basis of mismatch recognition by a SARS-CoV-2 proofreading enzyme |
| Q107341961 | Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN |
| Q110951004 | Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN |
| Q107981572 | The nucleotide addition cycle of the SARS-CoV-2 polymerase |
| Q110477732 | The nucleotide addition cycle of the SARS-CoV-2 polymerase |
Search more.